4.13
price down icon0.24%   -0.010
after-market Handel nachbörslich: 4.14 0.010 +0.24%
loading
Schlusskurs vom Vortag:
$4.14
Offen:
$4.07
24-Stunden-Volumen:
449.12K
Relative Volume:
0.52
Marktkapitalisierung:
$396.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-238.77M
KGV:
-0.1541
EPS:
-26.808
Netto-Cashflow:
$-216.62M
1W Leistung:
+6.44%
1M Leistung:
+36.75%
6M Leistung:
-44.79%
1J Leistung:
-67.45%
1-Tages-Spanne:
Value
$4.00
$4.28
1-Wochen-Bereich:
Value
$3.75
$4.28
52-Wochen-Spanne:
Value
$2.7601
$13.11

Alumis Inc Stock (ALMS) Company Profile

Name
Firmenname
Alumis Inc
Name
Telefon
650-231-6625
Name
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Mitarbeiter
184
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ALMS's Discussions on Twitter

Vergleichen Sie ALMS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALMS
Alumis Inc
4.13 427.20M 0 -238.77M -216.62M -26.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-25 Eingeleitet Wells Fargo Overweight
2025-06-10 Fortgesetzt Guggenheim Buy
2025-01-30 Eingeleitet Oppenheimer Outperform
2024-10-31 Eingeleitet Robert W. Baird Outperform
2024-10-17 Eingeleitet H.C. Wainwright Buy
2024-07-23 Eingeleitet Cantor Fitzgerald Overweight
2024-07-23 Eingeleitet Guggenheim Buy
2024-07-23 Eingeleitet Leerink Partners Outperform
2024-07-23 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Alumis Inc Aktie (ALMS) Neueste Nachrichten

pulisher
01:35 AM

How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - jammulinksnews.com

01:35 AM
pulisher
Jul 31, 2025

When is Alumis Inc. stock expected to show significant growthBreakout Stocks Updates With Proven Results - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What institutional investors are buying Alumis Inc. stockTop Growth Planner For Every Investor - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - jammulinksnews.com

Jul 30, 2025
pulisher
Jul 30, 2025

What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Alumis (ALMS) Merges with ACELYRIN - Insider Monkey

Jul 29, 2025
pulisher
Jul 28, 2025

What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Alumis Inc. company’s balance sheetTop Growth Entry Points With Low Risk - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Alumis Inc. generate profit in a changing economyInvest confidently with professional advice - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Alumis Inc. stockUnlock your trading potential today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are analysts’ price targets for Alumis Inc. in the next 12 monthsHigh-performance investment picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 26, 2025

Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis initiated with an Overweight at Wells Fargo - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Alumis Inc. stock priceUnbelievable profit margins - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis completes enrollment in lupus treatment phase 2b trial By Investing.com - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis completes enrollment in lupus treatment phase 2b trial - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026 - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Major Breakthrough: 408 Patients Enrolled in Advanced Trial for New Oral Lupus Treatment - Stock Titan

Jul 24, 2025

Finanzdaten der Alumis Inc-Aktie (ALMS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alumis Inc-Aktie (ALMS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Tananbaum James B.
Director
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
Foresite Labs, LLC
10% Owner
May 02 '25
Buy
4.62
25,000
115,500
4,227,670
Foresite Labs, LLC
10% Owner
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
Foresite Capital Management VI
10% Owner
May 02 '25
Buy
4.62
25,000
115,500
4,227,670
Foresite Capital Management VI
10% Owner
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
AKKARAJU SRINIVAS
Director
May 05 '25
Buy
4.67
160,370
749,676
3,586,788
AKKARAJU SRINIVAS
Director
May 02 '25
Buy
4.55
159,920
727,636
3,426,418
Colowick Alan
Director
Apr 01 '25
Buy
6.97
16,104
112,309
16,104
Colowick Alan
Director
Apr 02 '25
Buy
7.49
2,300
17,235
18,404
Babler Martin
President, CEO and Chairman
Apr 01 '25
Buy
6.44
15,650
100,733
106,454
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Kapitalisierung:     |  Volumen (24h):